brenetafusp
Protein / enzyme therapeutic
Evidence outlook · registrational
Cutaneous Melanoma: registrational readout pending
No completed mid-stage readout is on record. Registrational readout expected around 2027-10-16.
Company guidance: data expected later this year (Immunocore Holdings plc, 6 Nov 2026). “We expect to present clinical data for brenetafusp from the ovarian and lung cohorts in the Phase 1/2 trial at a medical conference later this year.” Source ↗
The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT06112314 NCT06112314 · Cutaneous Melanoma Registry: NCT06112314 | 3 | Progression-Free Survival (PFS) (Up to ~45 months) 2027-10-16 | In progress: results expected 16 Oct 2027 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (1)
What this study did
Phase 2 (1)
What this study did
Phase 1/2 (1)
What this study did
Competitive landscape
This drug's own stage for Cutaneous Melanoma: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Brenetafusp: this drug | Phase 3 | Protein / enzyme therapeutic | PRAME antigen presented on HLA-A*02:01 | not yet graded | No reviewed efficacy summary in this indication | |
| Ipilimumab | Approved | Monoclonal antibody | CTLA-4 antagonist | Partial signal | No reviewed efficacy summary in this indication |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow brenetafusp to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.